Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Former Cordis chairman joins board of stent start-up

This article was originally published in Clinica

Executive Summary

Privately-held stent developer Svelte Medical Systems has elected Robert Croce, a former worldwide franchise chairman of Johnson & Johnson-subsidiary Cordis, to its board of directors. Mr Croce spent 36 years at Johnson & Johnson, 12 of these as company group chairman. The appointment comes after Svelte completed an extension to its series A financing. The New Providence, New Jersey firm first announced it had raised the additional $6m in December, bringing the total investment in the company to $20m (, 9 December 2009). Investors in the firm include CNF Investments, Apjohn Ventures, the Fischell family and Norwich Ventures. Founded in 2007, Svelte is developing its Stent-on-a-Wire system, which is described as "a low-profile, highly flexible stent system which navigates the vasculature in a similar fashion to a traditional guidewire". The company initiated European clinical trials of the device in January and is looking to CE mark the product in the middle of this year, with a drug-eluting version to follow in 2011 (, 11 January 2010).

You may also be interested in...

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts